GABAPENTIN CAPSULES

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
21-08-2009

Aktiivinen ainesosa:

GABAPENTIN

Saatavilla:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC-koodi:

N02BF01

INN (Kansainvälinen yleisnimi):

GABAPENTIN

Annos:

300MG

Lääkemuoto:

CAPSULE

Koostumus:

GABAPENTIN 300MG

Antoreitti:

ORAL

Kpl paketissa:

30/100/500

Prescription tyyppi:

Prescription

Terapeuttinen alue:

MISCELLANEOUS ANTICONVULSANTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0125929003; AHFS:

Valtuutuksen tilan:

CANCELLED PRE MARKET

Valtuutus päivämäärä:

2023-07-24

Valmisteyhteenveto

                                _ _
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
GABAPENTIN CAPSULES
Gabapentin Capsules USP
100 mg, 300 mg, and 400 mg
Antiepileptic Agent
Ranbaxy Pharmaceuticals Canada Inc., Date of Preparation: August 20,
2009.
2680 Matheson Blvd. E., Suite 200
Mississauga, Ontario
L4W 0A5
Submission Control No: 132106
_ _
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
....…...........................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................3
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND
ADMINISTRATION..............................................................................13
OVERDOSAGE
................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND
STABILITY..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
....................................................................20
PHARMACEUTICAL
INFORMATION..........................................................................20
CLINICAL
TRIALS..........................................................................................................21
DETAILED
PHARMACOLOGY..............................................................
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia